Provided by Tiger Trade Technology Pte. Ltd.

Celldex Therapeutics

40.57
+0.19000.47%
Post-market: 40.570.00000.00%16:20 EDT
Volume:416.89K
Turnover:16.90M
Market Cap:3.18B
PE:-9.35
High:40.98
Open:40.16
Low:39.53
Close:40.38
52wk High:45.14
52wk Low:21.34
Shares:78.49M
Float Shares:73.02M
Volume Ratio:0.43
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3401
EPS(LYR):-3.9000
ROE:-43.88%
ROA:-27.62%
PB:4.46
PE(LYR):-10.40

Loading ...

BUZZ-Celldex climbs after Barclays' double upgrade

Reuters
·
Apr 20

Celldex Therapeutics : Barclays Raises to Overweight From Underweight

THOMSON REUTERS
·
Apr 20

Celldex upgraded to Overweight from Underweight at Barclays

TIPRANKS
·
Apr 20

U.S. RESEARCH ROUNDUP-Carpenter Technology, IBM, Ulta Beauty

Reuters
·
Apr 20

Celldex to join H.C. Wainwright inflammatory skin disease conference fireside chat

Reuters
·
Apr 14

A Look At Celldex Therapeutics (CLDX) Valuation After Equity Raise And New Barzolvolimab Data

Simply Wall St.
·
Apr 08

Celldex closes common stock offering, raises about $345 million gross proceeds

Reuters
·
Apr 06

Did Celldex’s (CLDX) US$300 Million Equity Raise to Fund Barzolvolimab Just Shift Its Investment Narrative?

Simply Wall St.
·
Apr 05

Celldex Therapeutics Inc - Offers 10,345,000 Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Apr 03

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Escalation Signals in Iran Conflict Lift Oil Prices

MT Newswires Live
·
Apr 02

BUZZ-U.S. STOCKS ON THE MOVE-Globalstar, Wingstop, US energy stocks

Reuters
·
Apr 02

BRIEF-Celldex Announces Pricing Of $300 Million Public Offering Of Common Stock

Reuters
·
Apr 02

Celldex Therapeutics Inc - Prices Public Offering of 10,345,000 Shares at $29.00 per Share

THOMSON REUTERS
·
Apr 02

BUZZ-Celldex Therapeutics drops on unveiling stock offering

Reuters
·
Apr 02

Celldex commences underwritten public offering of common stock

Reuters
·
Apr 02

Celldex Announces Proposed Public Offering of Common Stock

THOMSON REUTERS
·
Apr 02

BRIEF-Celldex Therapeutics Presents Positive Phase 2 Data For Barzolvolimab In CSU, ColdU, And SD

Reuters
·
Mar 27

Celldex data shows improvements across six DLQI Domains in barzolvolimab trials

TIPRANKS
·
Mar 27

Celldex Therapeutics Inc - Presents Positive Phase 2 Data for Barzolvolimab in Csu, Coldu, and Sd

THOMSON REUTERS
·
Mar 27

Celldex presents Phase 2 barzolvolimab data; CSU complete response reaches 71% at Week 52 due to sustained symptom control

Reuters
·
Mar 27